Exelixis Explains Cabozantinib Thyroid Cancer Delay As Prostate Program Takes Shape

The results from the event-driven pivotal trial of Exelixis Inc.’s cabozantinib in medullary thyroid cancer will be delayed by three more months, but there is a good chance for a positive outcome.